High cloning capacity of in vitro packaged SV40 vectors with no SV40 virus sequences

Human Gene Therapy

Volumn 14, Issue 2, 2003, Pages 167-177

  Kimchi Sarfaty, Chava ^a   Arora, Mili ^a   Sandalon, Ziv ^b,c   Oppenheim, Ariella ^b   Gottesman, Michael M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HEBREW UNIVERSITY   (Israel)

^c Targeted Genetics Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; CALCEIN; CAPSID PROTEIN; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PHORBOL 13 ACETATE 12 MYRISTATE; PLASMID DNA; PROTEIN AGNO; PROTEIN MXR; PROTEIN VP1; PROTEIN VP2; PROTEIN VP3; RHODAMINE 123; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VECTOR;

ARTICLE; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA PACKAGING; ELECTRON MICROSCOPY; FLUORESCENCE ACTIVATED CELL SORTER; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SIMIAN VIRUS 40; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID;

CELL LINE; CLONING, MOLECULAR; GENETIC VECTORS; HUMANS; PLASMIDS; SIMIAN VIRUS 40; VIRUS ASSEMBLY;

SIMIAE; SIMIAN VIRUS 40;

EID: 0037255009     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303403321070865     Document Type: Article

References (40)

1. AGRAWAL, S., and KISHORE, M.C. (2000). MHC class I gene expression and regulation. J. Hematother. Stem Cell Res. 9, 795-812.
2. ARAN, J.M., PASTAN, I., and GOTTESMAN, M.M. (1999). Therapeutic strategies involving the multidrug resistance phenotype: The MDR1 gene as target, chemoprotectant, and selectable marker in gene therapy. Adv. Pharmacol. 46, 1-42.
3. BINA, M. (1986). Simian virus 40 assembly. Comments Mol. Cell Biophys. 4, 55-62.
4. CARDARELLI, C.O., AKSENTIJEVICH, I., PASTAN, I., and GOTTESMAN, M.M. (1995). Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters. Cancer Res. 55, 1086-1091.
5. CORMACK, B.P., VALDIVIA, R.H., and FALKOW, S. (1996). FACS-optimized mutants of the green fluorescent protein (GFP). Gene 173, 33-38.
6. DALYOT-HERMAN, N., BEN-NUN-SHAUL, O., GORDON-SHAAG, A., and OPPENHEIM, A. (1996). The simian virus 40 packaging signal ses is composed of redundant DNA elements which are partly interchangeable. J. Mol. Biol. 259, 69-80.
7. FIBISON, W.J. (2000). Gene therapy. Nurs. Clin. North Am. 35, 757-772.
8. GORDON-SHAAG, A., BEN-NUN-SHAUL, O., ROITMAN, V., YOSEF, Y., and OPPENHEIM, A. (2002). Cellular transcription factor SP1 recruits the SV40 capsid proteins to the viral packaging signal ses. J. Virol. 76, 5915-5924.
9. GOTTESMAN, M.M. (2002). Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615-627.
10. GOTTESMAN, M.M., GERMANN, U.A., AKSENTIJEVICH, I., SUGIMOTO, Y., CARDARELLI, C.O., and PASTAN, I. (1994). Gene transfer of drug resistance genes. Implications for cancer therapy. Ann. N.Y. Acad. Sci. 716, 126-138; discussion 138-143.
11. HAFKEMEYER, P., LICHT, T., PASTAN, I., and GOTTESMAN, M.M. (2000). Chemoprotection of hematopoietic cells by a mutant P-glycoprotein resistant to a potent chemosensitizer of multidrug-resistant cancers. Hum. Gene Ther. 11, 555-565.
12. HARMS, J.S., and SPLITTER, G.A. (1995). Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. Hum. Gene Ther. 6, 1291-1297.
13. HODGSON, C.P. (1995). The vector void in gene therapy. Biotechnology 13, 222-225.
14. KAVATHAS, P., BACH, F.H., and Demars, R. (1980). Gamma ray-induced loss of expression of HLA and glyoxalase I alleles in lymphoblastoid cells. Proc. Natl. Acad. Sci. U.S.A. 77, 4251-4255.
15. KIMCHI-SARFATY, C., BEN-NUN-SHAUL, O., RUND, D., OPPENHEIM, A., and GOTTESMAN, M.M. (2002a). In vitro-packaged SV40 pseudovirions as highly efficient vectors for gene transfer. Hum. Gene Ther. 13, 299-310.
16. KIMCHI-SARFATY, C., GRIBAR, J., and GOTTESMAN, M.M. (2002b). Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol. Pharmacol. 62, 1-6.
17. KOTARSKY, K., OWMAN, C., and OLDE, B. (2001). A chimeric reporter gene allowing for clone selection and high- throughput screening of reporter cell lines expressing G-protein-coupled receptors. Anal. Biochem. 288, 209-215.
18. LEE, C.G., VIEIRA, W.D., PASTAN, I., and GOTTESMAN, M.M. (2001). An episomally maintained MDR1 gene for gene therapy. Hum. Gene Ther. 12, 945-953.
19. LI, P.P., NAKANISHI, A., CLARK, S.W., and KASAMATSU, H. (2002). Formation of transitory intrachain and interchain disulfide bonds accompanies the folding and oligomerization of simian virus 40 VP1 in the cytoplasm. Proc. Natl. Acad. Sci. U.S.A. 99, 1353-1358.
20. LI, P.P., NAKANISHI, A., SHUM, D., SUN, P.C., SALAZAR, A.M., FERNANDEZ, C.F., CHAN, S.W., and KASAMATSU, H. (2001). Simian virus 40 VP1 DNA-binding domain is functionally separable from the overlapping nuclear localization signal and is required for effective virion formation and full viability. J. Virol. 75, 7321-7329.
21. LICHT, T., GOTTESMAN, M.M., and PASTAN, I. (1995). Transfer of the MDR1 (multidrug resistance) gene: Protection of hematopoietic cells from cytotoxic chemotherapy, and selection of transduced cells in vivo. Cytokines Mol. Ther. 1, 11-20.
22. LIDDINGTON, R.C., YAN, Y., MOULAI, J., SAHLI, R., BENJAMIN, T.L., and HARRISON, S.C. (1991). Structure of simian virus 40 at 3.8-A resolution. Nature 354, 278-284.
23. LITMAN, T., DRULEY, T.E., STEIN, W.D., and BATES, S.E. (2001). From MDR to MXR: New understanding of multidrug resistance systems, their properties and clinical significance. Cell. Mol. Life Sci. 58, 931-959.
24. NORKIN, L.C. (1999). Simian virus 40 infection via MHC class I molecules and caveolae. Immunol. Rev. 168, 13-22.
25. NORKIN, L.C. (2001). Caveolae in the uptake and targeting of infectious agents and secreted toxins. Adv. Drug Deliv. Rev. 49, 301-315.
26. NORKIN, L.C., ANDERSON, H.A., WOLFROM, S.A., and OPPENHEIM, A. (2002). Caveolae-mediated simian virus 40 entry is followed by brefeldin A-sensitive transport to the endoplasmic reticulum where the virus disassembles. J. Virol. 76, 5156-5166.
27. OPPENHEIM, A., SIANI, M., SANDALON, Z., and MENGERITSKY, G. (1994). Dynamics of the nucleoprotein structure of simian virus 40 regulatory region during viral development. J. Mol. Biol. 238, 501-513.
28. PELKMANS, L., KARTENBECK, J., and HELENIUS, A. (2001). Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat. Cell Biol. 3, 473-483.
29. ROBBINS, P.D., and GHIVIZZANI, S.C. (1998). Viral vectors for gene therapy. Pharmacol. Ther. 80, 35-47.
30. RUND, D., DAGAN, M., DALYOT-HERMAN, N., KIMCHI-SARFATY, C., SCHOENLEIN, C., GOTTESMAN, M.M., and OPPENHEIM, A. (1998). Efficient transduction of human hematopoietic cells with the human multidrug resistance gene 1 via SV40 pseudovirions. Hum. Gene Ther. 9, 649-657.
31. SANDALON, Z., and OPPENHEIM, A. (1997). Self-assembly and protein-protein interactions between the SV40 capsid proteins produced in insect cells. Virology 237, 414-421.
32. SANDALON, Z., and OPPENHEIM, A. (2001). Production of SV40 proteins in insect cells and in vitro packaging of virions and pseudovirions. Methods Mol. Biol. 165, 119-128.
33. SANDALON, Z., DALYOT-HERMAN, N., OPPENHEIM A.B., and OPPENHEIM, A. (1997). In vitro assembly of SV40 virions and pseudovirions: Vector development for gene therapy. Hum. Gene Ther. 8, 843-849.
34. STEHLE, T., GAMBLIN, S.J., YAN, Y., and HARRISON, S.C. (1996). The structure of simian virus 40 refined at 3.1 A resolution. Structure 4, 165-182.
35. STRAYER, D.S. (1999a). Gene delivery to human hematopoietic progenitor cells to address inherited defects in the erythroid cellular lineage. J. Hematother. Stem Cell Res. 8, 573-574.
36. STRAYER, D.S. (1999b). Gene therapy using SV40-derived vectors: What does the future hold? J. Cell. Physiol. 181, 375-384.
37. STRAYER, D.S. (2000). Effective gene transfer using viral vectors based on SV40. Methods Mol. Biol. 133, 61-74.
38. SUGIMOTO, Y., AKSENTIJEVICH, I., MURRAY, G.J., BRADY, R.O., PASTAN, I., and GOTTESMAN, M.M. (1995). Retroviral co-expression of a multidrug resistance gene (MDR1) and human α-galactosidase A for gene therapy of Fabry disease. Hum. Gene Ther. 6, 905-915.
39. TOOZE, J. (1981). DNA Tumor Viruses. Cold Spring Harbor Laboratory, New York.
40. ZHOU, S., SCHUETZ, J.D., BUNTING, K.D., COLAPIETRO, A.M., SAMPATH, J. MORRIS, J.J., LAGUTINA, I., GROSVELD, G.C., OSAWA, M., NAKAUCHI, H., and SORRENTINO, B.P. (2001). The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 7, 1028-1034.